NewAmsterdam Pharma (NAMS) news
Recent news
NewAmsterdam Pharma doses first participant in phase 2B Spinoza trial evaluating obicetrapib in preclinical Alzheimer’s disease
AInvest Wire · Sep 29, 2026New Amsterdam Pharma, Menarini get EC OK for Ubeslo, Evlarc
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) and its partner Menarini Group have received marketing authorization from the European Commission for Ubeslo® (obicetrapib 10 mg monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination) for the treatment of primary…
AInvest Wire · Sep 21, 2026NewAmsterdam Pharma reports inducement grants under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Aug 6, 2026NewAmsterdam Pharma Company N.V. - topline data from Rubens Phase 3 expected by year-end 2026
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) announced that RUBENS Phase 3 trial data is expected by year-end 2026. The RUBENS trial is evaluating obicetrapib, either alone or in combination with ezetimibe, in type 2 diabetes or metabolic syndrome patients who require additional LDL-C lowering…
AInvest Wire · Aug 5, 2026NewAmsterdam Pharma Company N.V. - Prevail interim analysis planned for Q4 2026, result expected Q1 2027
AInvest Wire · Aug 5, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.